Recorlev strength drives 29% revenue jump for Xeris in Q2, but debt extinguishment loss sinks bottom line
XERS sits 40% above its 52-week low of $5.25 on elevated volume (1.9× avg).
Summary
Xeris Biopharma reported Q2 2026 revenue of $92.1 million, a 29% increase driven by Recorlev, but a non-cash debt extinguishment loss of $30.8 million resulted in a net loss of $31.1 million. The company retired all remaining convertible notes in July, strengthening the balance sheet.
Key Events · Earnings and Guidance · XERS
-
Recorlev Revenue Surges 81%
Recorlev net revenue reached $56.8 million in Q2 2026, an 80.6% increase year-over-year, driven by higher patient demand and favorable pricing.
-
Non-Cash Debt Extinguishment Loss
A $30.8 million non-cash loss was recognized from an exchange agreement on 2028 convertible notes, representing the difference between amortized cost and fair value.
-
Positive Operating Cash Flow
Net cash provided by operating activities was $18.1 million for the first half of 2026, a significant improvement from a $9.8 million use of cash in the prior year period.
-
Convertible Notes Fully Retired
In July 2026, the company settled all remaining 2028 convertible notes, issuing 8.6 million shares and paying $23.0 million in cash, eliminating $33.6 million in debt.
Analysis · XERS · Life Sciences
Strong top-line growth was fueled by Recorlev revenue nearly doubling year-over-year, yet a $30.8 million non-cash loss from retiring convertible notes pushed the bottom line deep into the red. The company generated positive operating cash flow and ended the quarter with $121.7 million in cash, providing ample runway. The subsequent elimination of all remaining 2028 convertible notes removes a significant overhang, though the chief legal officer's newly adopted 10b5-1 plan to sell up to 300,000 shares warrants attention.
At the time of this filing, XERS was trading at $7.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.25 to $10.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.